"This is not an ATM cause your broke..."
But it's just a matter of time, Gusty, and not much of that. Maybe till the end of the year?
I think the FDA is just pimping their favor on whoever the benefactor may be. The delayed regulatory approval causes not only competitive disadvantage for us, it puts the company under tremendous financial pressure as well. Makes us just ripe for the picking.
I think resuming the Controlled Equity Offering was not the company's pre-planned intention. It only became necessary because we have been prohibited from starting a revenue stream.
I hope the UK and the EU make that happen for us, which they may not have, if we actually scaled back the commercial production of lenz.
What we have is a determined management team that is going to get us across the goal line. I'm proud of these guys!